Thursday 16 October, 2025
Objectives: Atypical antipsychotic risperidone (RISP) undergoes extensive CYP2D6 and CYP3A4 catalyzed hydroxylation to active 9-hydroxyrisperidone enantiomers (9OH-RISP) [1]. Large interindividual…
Read morePoster: Applications- CNS
Pool Model versus Agonist-Antagonist Interaction Model for the Remoxipride Effect on Prolactin
Thursday 16 October, 2025
Objectives: The pool model [1] has previously been shown to be inferior to an agonist-antagonist interaction (AAI) model [2, 3]…
Read moreA population pharmacokinetic/pharmacodynamic model for duloxetine in diabetic peripheral neuropathy, plus methods for handling missing data.
Thursday 16 October, 2025
Objectives: Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of diabetic peripheral neuropathic pain…
Read moreScaling propofol doses for the obese: is lean body weight the answer?
Thursday 16 October, 2025
Objectives: Longer awakening times have been observed in obese compared to normal-weight patients when propofol is dosed on total body…
Read morePopulation Pharmacokinetics of Safinamide and its Effect on Disease Progression in Parkinson’s Disease
Thursday 16 October, 2025
Background: Safinamide (SAF), a first-in-class agent in Parkinson's disease (PD), is an α-aminoamide derivative with dopaminergic and non-dopaminergic mechanisms of…
Read moreTowards Quantitative Prediction Of In Vivo Brain Penetration Using A Physiology Based CNS Disposition Model
Thursday 16 October, 2025
Background: Drug discovery for CNS disorders has been challenged with markedly high attrition rate. This has driven extensive preclinical and…
Read morePopulation PK/PD of Alprazolam in the Attenuation of ACTH Activation Induced by Cognitive Performance in Metyrapone-treated Healthy Volunteers
Thursday 16 October, 2025
Objectives: The control of ACTH release from the pituitary is under hormonal controls. Stimulating effects are produced by the peptide…
Read moreCould prolactin levels be a more informative predictor for clinical effect of D2-receptor antagonists than drug concentrations in the treatment of schizophrenia?
Thursday 16 October, 2025
Objectives: In a setting with many simultaneously ongoing processes and high variability like in schizophrenia a clear drug concentration-effect relationship…
Read morePopulation Pharmacokinetics of Midazolam and Metabolites during Venoarterial Extracorporeal Membrane Oxygenation in Neonates
Thursday 16 October, 2025
Objectives: Midazolam is used to sedate neonates during extracorporeal membrane oxygenation (ECMO). During the procedure, midazolam pharmacokinetics are expected to…
Read moreADAS-Cog Placebo Modelling in Alzheimer’s Disease
Thursday 16 October, 2025
Background: The cognitive portion of the Alzheimer Disease Assessment Scale (ADAS-Cog) is the standard cognitive endpoint for clinical trials of…
Read more